A rare twist after Ex-vivo RIRS: graft parenchymal urine leak in a living donor kidney.

CEN Case RepOct 26, 2026 (epub)
Case ReportUrologyOpen access

Asad Bashir, Nasrum Minallah, Fiaz Ahmed Touqeer et al.

✦ AI-curated · Sources linked

Case in brief

A 29-year-old man received a living-donor kidney after ex-vivo retrograde intrarenal surgery (RIRS) to remove a 5 mm upper-pole calculus. Postoperatively, bloody drain output led to re-exploration, which identified a capsular tear. When the drainage became clear, elevated drain-fluid creatinine and CT urography confirmed a graft parenchymal urine leak. The bleeding was managed surgically; the leak was treated conservatively with prolonged drainage and a double-J stent. Graft function remained stable.

What made this case unusual

The report describes graft parenchymal urine leakage after ex-vivo RIRS in a living-donor kidney transplant, an exceptionally rare complication according to the authors.

Diagnostic / clinical pearl

Clear postoperative drain output after bleeding from a capsular tear may represent a parenchymal urine leak; drain-fluid creatinine and CT urography helped confirm the diagnosis in this case.

Why it matters

The authors emphasize controlling irrigation pressure during ex-vivo RIRS and promptly identifying complications to help preserve graft function.

Source

Published in CEN Case Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.